LB Pharmaceuticals Cash Flow From Operations vs. Net Income

LBRX Stock   22.15  0.39  1.73%   
Based on LB Pharmaceuticals' profitability indicators, LB Pharmaceuticals Common may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess LB Pharmaceuticals' ability to earn profits and add value for shareholders.
Current ValueLast YearChange From Last Year 10 Year Trend
Return On Equity0.360.6674
Way Down
Pretty Stable
For LB Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of LB Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well LB Pharmaceuticals Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between LB Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of LB Pharmaceuticals Common over time as well as its relative position and ranking within its peers.
Check out Correlation Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LB Pharmaceuticals. If investors know LBRX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LB Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of LB Pharmaceuticals Common is measured differently than its book value, which is the value of LBRX that is recorded on the company's balance sheet. Investors also form their own opinion of LB Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is LB Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LB Pharmaceuticals' market value can be influenced by many factors that don't directly affect LB Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LB Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if LB Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LB Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

LB Pharmaceuticals Common Net Income vs. Cash Flow From Operations Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining LB Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare LB Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
LB Pharmaceuticals Common is currently regarded as number one stock in cash flow from operations category among its peers. It also is currently regarded as number one stock in net income category among its peers . LB Pharmaceuticals reported Net Loss of (63.1 Million) in 2024. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the LB Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

LBRX Net Income vs. Cash Flow From Operations

Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

LB Pharmaceuticals

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
(53.05 M)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

LB Pharmaceuticals

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(63.1 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

LBRX Net Income Comparison

LB Pharmaceuticals is currently under evaluation in net income category among its peers.

LB Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in LB Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, LB Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of LB Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of LB Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income111 K154 K
Net Interest Income1.7 M1.8 M
Interest Income1.7 M955.2 K
Operating Income-64.8 M-61.6 M
Net Loss-63.1 M-59.9 M
Income Before Tax-63.1 M-59.9 M
Total Other Income Expense Net1.7 M1.8 M
Net Loss-63.1 M-59.9 M
Income Tax Expense 900.00  800.00 
Net Loss(17.83)(16.94)
Income Quality 0.84  0.79 
Net Income Per E B T 1.00  1.10 

LBRX Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on LB Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of LB Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the LB Pharmaceuticals' important profitability drivers and their relationship over time.

Use LB Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if LB Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in LB Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

LB Pharmaceuticals Pair Trading

LB Pharmaceuticals Common Pair Trading Analysis

The ability to find closely correlated positions to LB Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace LB Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back LB Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling LB Pharmaceuticals Common to buy it.
The correlation of LB Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as LB Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if LB Pharmaceuticals Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for LB Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your LB Pharmaceuticals position

In addition to having LB Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Books Thematic Idea Now

Books
Books Theme
Companies involved in publishing of books, newspapers, periodicals and other mass publications. The Books theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Books Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for LBRX Stock Analysis

When running LB Pharmaceuticals' price analysis, check to measure LB Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LB Pharmaceuticals is operating at the current time. Most of LB Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of LB Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LB Pharmaceuticals' price. Additionally, you may evaluate how the addition of LB Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.